We describe novel mutants of herpes simplex virus which are resistant to aphidicolin. Their mutant phenotypes suggest that they encode DNA polymerases with altered substrate recognition. This conclusion is based on their abnormal sensitivity to polymerase inhibitors and to the abnormal mutation rates exhibited by two of the mutants.
We describe novel mutants of herpes simplex virus which are resistant to aphidicolin. Their mutant phenotypes suggest that they encode DNA polymerases with altered substrate recognition. This conclusion is based on their abnormal sensitivity to polymerase inhibitors and to the abnormal mutation rates exhibited by two of the mutants.
Aphidicolin is a potent inhibitor of many DNA polymerases, including DNA polymerase alpha from eucaryotic cells and DNA polymerases from herpesviruses (6, 9, 13, 17, 21, 22, 24) . This drug appears useful for studying interactions between DNA polymerases and deoxyribonucleotide triphosphate (dNTP) substrates, since aphidicolin interferes with dNTP binding (5, 7, 13) . Consequently, a subset of polymerase residues which interact with aphidicolin should also bind dNTPs, and mutants with altered sensitivity to this drug should help identify such residues.
In accord with this prediction, several previously characterized aphidicolin mutants encode DNA polymerases which exhibit altered substrate interactions (i.e., altered affinities for dNTPs and for certain substrate analogs; 8, 10, 12, 16, 18, 23) . Some mutants also exhibit mutator or antimutator phenotypes, suggesting alterations in their abilities to select correctly base-paired substrates (1, 11, 16, 19) . Among the mutants from herpes simplex virus type 1 (HSV-1), several are hypersensitive to aphidicolin (8) , but only two resistant viral mutants known to carry polymerase changes have been reported, one moderately resistant mutant from HSV-1 (14) and one from the closely related HSV-2 (18) .
Several other polymerase inhibitors have been useful for isolating mutants from HSV-1 which affect substrate recognition. These inhibitors include substrate analogs with altered ribose rings [e.g., acycloguanosine, arabinosyladenine (araA), and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG)] and phosphonoacetic acid. The analogs are phosphorylated in herpesvirus-infected cells. Once utilized by the polymerase as substrates, they inhibit further replication (2) (3) (4) 20) . Since these analogs mimic normal substrates, mutants with altered sensitivity to these compounds appear to carry changes which affect substrate recognition. Phosphonoacetic acid has also been used to isolate substrate-specificity mutants, since mutants resistant to this drug also exhibit altered sensitivity to the substrate analogs (8, 15 virus sequentially in increasing concentrations of aphidicolin. TC7 cells (11) were inoculated with the KOS strain of HSV-1 at 0.1 PFU per cell in the presence of 0.12 jg of drug per ml. Plaque-purified stocks (11) were used to assure independent isolation of mutants from different infections. Progeny virus were then grown sequentially in 0.25, 0.5, and 0.6 jig of aphidicolin per ml. Drug-resistant plaques were selected and plaque purified in the absence of drug. Mutants Aph'-10 and Aph'-12 were isolated from the same stock, but both were studied since they exhibit different phenotypes. Mutants Aphr14 and Aphr16 were isolated from separate stocks.
Mapping of the mutations. We have cloned regions of the DNA polymerase gene from each mutant and shown by marker rescue experiments that recombinants which incorporate the cloned sequences acquire resistance to aphidicolin (J. Hall, S. Woodward, and M. Berlin, manuscript in preparation). Two such recombinants were recovered from each mapping experiment, and their phenotypes were characterized as described below (i.e., drug sensitivities, spontaneous mutation rates). In each case, the recombinants showed the same phenotypes as the original mutants (data not shown; Table 1 ). Consequently, the phenotypes described below for the original mutants most likely result from the aphidicolin resistance mutations.
Sensitivity to DNA polymerase inhibitors. The resistance of these mutants to aphidicolin is shown in Fig. 1A . Drug The effects of other inhibitors on plaque survival are shown in Fig. 1B through F and are summarized in Table 2 . Although all the mutants are more sensitive to DHPG than is the wild-type virus (Fig. 1F) phonoacetic acid and are hypersensitive to araT. AphrlO and Aphr16 show near-normal sensitivities to araA and acycloguanosine, whereas Aphr12 and Aphr14 are hypersensitive to araA and are resistant to acycloguanosine. Because these mutants exhibit altered sensitivities to the substrate analog inhibitors (DHPG, araA, araT, and acycloguanosine), we conclude that they probably carry mutations which affect substrate recognition. The contrasting phenotypes of these mutants further suggest that at least two different mutations within the aphidicolin-binding site are involved.
Mutation frequencies. Since previously characterized aphidicolin-resistant mutants (from HSV-2 and rodent cells) are associated with a mutator phenotype (1, 16, 19), we measured the mutation frequencies for our mutants. The results are shown in Table 1 and were determined from the fractions of spontaneous viral mutants resistant to iododeoxycytidine (ICdR) in several parallel infections (11) .
Although AphrlO and Aphr16 are similar in their inhibitor sensitivities to the aphidicolin-resistant, mutator derivative from HSV-2 (19), they fail to exhibit this mutatqr phenotype. Aphr16 showed normal levels of ICdR-resistant mutant production. Although the average level for AphrlO was slightly higher than that for the wild type, most of the values fell within the wild-type range (data not shown), and recombinants from marker rescue experiments with AphrlO sequences showed normal mutation frequencies. Aphr12 and Aphr14 produce substantially fewer mutants than does wild type. However, they differ from previously studied antimutators from HSV-1 which are hypersensitive to aphidicolin (8, 11) . These observations provide support for the uniqueness of our mutants and suggest that the mutations within Aphr12 and Aphr14 (the antimutators) will identify new residues involved in substrate selection.
Conclusions. Our aphidicolin-resistant mutants show altered sensitivities to substrate analogs, suggesting that they carry DNA polymerase mutations which affect substrate recognition. These mutants differ from other herpesvirus drug-resistant mutants (8, 14, 18) 
